Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | NPY4R | P50391 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 5/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8745865 | 1.00 | DPP7 (0.43) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10292018 | 1.00 | DPP7 (0.43) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL16421890 | 0.95 | DPP7 (0.46) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL10190380 | 0.95 | DPP7 (0.46) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13320657 | 0.95 | DPP7 (0.46) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13434929 | 0.89 | ANPEP (0.37) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12278048 | 0.89 | ANPEP (0.37) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL8125131 | 0.89 | ANPEP (0.37) | DPP7NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL18542868 | 0.87 | DPP7 (0.44) | DPP7OTCGNAI3GNAO1GNAI1 | |
| SCHEMBL19368710 | 0.87 | DPP7 (0.44) | DPP7OTCGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | claimed |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| US-20220162261-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2022-05-26 | — | — | US | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3570864-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4025592-B1 | CONJUGATED HEPCIDIN MIMETICS FOR USE IN TREATING OF POLYCYTHEMIA VERA | PROTAGONIST THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2008040979-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | ARK THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | DPP7 224/4885NPY4R 1784/4885NPY1R 2900/4885 |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | DPP7 224/4885NPY4R 1784/4885NPY1R 2900/4885 |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | DPP7 737/4885NPY4R 597/4885NPY1R 730/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | DPP7 826/4885NPY4R 204/4885NPY1R 38/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | DPP7 224/4885NPY4R 1567/4885NPY1R 2518/4885 |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | ARG1, NRDC, CHIA | DPP7 305/4885NPY4R 593/4885NPY1R 840/4885 |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | GLP1R, GIPR, NPY1R | DPP7 90/4885NPY4R 7/4885NPY1R 3/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | DPP7 175/4885NPY4R 579/4885NPY1R 61/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | DPP7 290/4885NPY4R 943/4885NPY1R 1444/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | DPP7 175/4885NPY4R 1132/4885NPY1R 1601/4885 |
| US-20220162261-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | DPP7 138/4885NPY4R 630/4885NPY1R 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.